




Q2FY23 || November 2022

BSE: 543266 | NSE: HERANBA | ISIN: INE694N01015

www.heranba.co.in





This presentation and the accompanying slides (the "Presentation"), which have been prepared by Heranba Industries Limited (the "Company"), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any securities, and shall not form the basis or be relied on in connection with any contract or binding commitment whatsoever. No offering of securities of the Company will be made except by means of a statutory offering document containing detailed information about the Company.

This Presentation has been prepared by the Company based on information and data which the Company considers reliable, but the Company makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this Presentation. This Presentation may not be all inclusive and may not contain all of the information that you may consider material. Any liability in respect of the contents of, or any omission from, this Presentation is expressly excluded

Certain matters discussed in this Presentation may contain statements regarding the Company's market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. These risks and uncertainties include, but are not limited to, the performance of the Indian economy and of the economies of various international markets, the performance of the industry in India and world-wide, competition, the company's ability to successfully implement its strategy, the Company's future levels of growth and expansion, technological implementation, changes and advancements, changes in revenue, income or cash flows, the Company's market preferences and its exposure to market risks, as well as other risks. The Company's actual results, levels of activity, performance or achievements could differ materially and adversely from results expressed in or implied by this Presentation. The Company assumes no obligation to update any forward-looking information contained in this Presentation. Any forward-looking statements and projections made by third parties included in this Presentation are not adopted by the Company and the Company is not responsible for such third-party statements and projections.

### **Contents**

O1 Company Overview
SLIDE 04

**Management Team**SLIDE 11

**Quarterly Performance**SLIDE 13

**O4** Financial Performance
SLIDE 18

O5 Strategy for Growth SLIDE 25





Section: 01

**Company Overview** 

Heranba at glance

SLIDE 05

**Intermediaries** 

SLIDE 08

Our journey

SLIDE 06

**Technicals** 

SLIDE 09

Value chain

SLIDE 07

**Formulations** 

SLIDE 10




### Heranba at a Glance



Manufacturing **Facilities** 



65 +Countries Presence



700+ Employees (as of FY22)



60+ Revenue from Institutional customers\*\* (as of FY22)



9400+ Dealers across India



32% Revenue from Exports as % of sales (as of H1FY23)



~25% Revenue from Top 10 customers (as of FY22)



29.0% ROE# (as of H1FY23)

## **Our Journey**



#### **CMAC**

Started manufacturing the Intermediate CMAC



#### **FORMULATIONS**

Forward integrated into the manufacturing of Formulations developed from Company's synthetic pyrethroids product portfolio of cypermethrin, alphacypermethrin, deltamethrin, permitherin, lambda cyhalothrin



ISO

Receipt of ISO 9001:2015 certification in respect of production & dispatch of agro Formulations and packing & dispatch of agro based herbicides

#### **EXPORTS**

Exported Technicals and Formulations to more than 65+ countries in the international markets

1996

2002

2005

2006

2014

2019

2020

2021-22



#### **TECHNICALS**

Forward integrated into the manufacturing of Technicals, primarily made from the raw material CMAC and other Intermediates



### BRANDED FORMULATIONS

Forward Integrated into Branded Formulations through its own distribution network



#### **TURNOVER**

Achieved Turnover of ₹1000 Crores





### INITIAL PUBLIC OFFERING

Listed on BSE & NSE



Commissioned Unit No. 4 in Vapi

### **Value Chain**




### **Value Chain**

HIL over the years, has scaled up the manufacturing of Intermediates, Technicals and Formulations which form part of the entire value chain of the agrochemicals industry

### **Manufacturing Process**


- HIL manufactures a wide range of products, and each product has its own unique manufacturing process
- The Company specializes in the manufacturing processes that mainly include chemical reactions of:



 The process of manufacturing can be classified broadly into three stages



### **Intermediaries**





### **End-use**

Intermediates manufactured are for Company's own captive consumption for manufacturing various
Technicals and Formulations


### **Technicals**

### Insecticides

- Cypermethrin
- Deltamethrin
- Alpha Cypermethrin
- Acephate
- Lambda Cyhalothrin
- Permethrin
- Profenophos
- Temephos
- Theta Cypermethrin
- Thiamethoxam
- Imidacloprid

### Herbicides

- Glyphosate
- Metribuzin
- Clodinofop



### **Fungicides**


- Tricyclazole
- Hexaconazole



### **Formulations**


#### **Insecticides**

- Jayam
- Progress Plus
- Param
- Cypraplus
- Dyken
- Mantra
- Astron
- Signor
- Prompt
- Cypra
- Heraban
- Alpha Shakti
- Henoxa



Silicon Plus

#### **Revenue from Technical and Formulations**





Section: 02

Management




## **Experienced Promoters with Domain Knowledge**

Promoters having a cumulative experience of more than six decades



Mr. Sadashiv K. Shetty
Chairman and Executive Director



- Has an experience of more than three decades in agrochemicals industry
- Mr. Sadashiv K. Shetty is associated with the Company since 1994. He is a stalwart of the agrochemicals industry, with over thirty years of experience in the sector.
- Has galvanized the development of new products and is boosting the capacities & capabilities of the Company
- His skill, Experience & Expertise includes Business Leadership & Operations, Risk Management & Governance, Business Expertise, Strategic Planning, General Management, Functional & Managerial Experience Chemical Industry Expert, Manufacturing, Research & Development, etc.



Mr. Raghuram K. Shetty

Managing Director

- Holds a bachelor's degree in economics, Diploma in Export and Import Management and Commercial Diploma from Department of Education, Bureau of Government Examination
- Has an experience of more than three decades in agrochemicals industry
- Mr. Raghuram K. Shetty is associated with the Company since 1994
- In charge of the overall management and day-to-day affairs of the Company, while also giving shape to the future business strategies
- He is the driving force behind the Business Development, Business Operations, Risk Management & Governance, Finance & Accounting, Functional, Strategic Planning, Procurement, Sales & Marketing, Managerial Operations, International Trade, Export Business Management, Product Development, Plant Setup, Supply Chain, Intellectual Property Rights, etc.



Section: 03

# **Quarterly Performance**

**Management Commentary** 

SLIDE 14

**Quarterly Performance** 

SLIDE 15

**P&L Summary** 

SLIDE 16 & 17



## **Q2FY23 Management Commentary**

Mr. Raghuram K. Shetty, Managing Director of Heranba Industries Limited, commented, "The Company revenues surged by 19.8% YoY to ₹4,233 million in Q2FY23 driven by strong performance in domestic markets navigating uneven monsoon distribution. Our export business was impacted by the lockdown in China coupled with volatile global macroeconomics. Our EBITDA margins were under check due to higher raw material prices and a rise in power & fuel costs. The domestic agrochemical industry is likely to do well in H2FY23 due to residual moisture owing to the late withdrawal of the southwest monsoon, higher reservoir levels and a rise in MSP (Minimum Support Prices) of Rabi crops for the upcoming 2023-24 marketing season.


We have spent ₹ 410 million on capex at our Sarigam facility during H1FY23 and will be spending additional ₹ 1,000 million in H2FY23. The commercial production of technical grade pesticides and intermediates from Sarigam facility is likely to commence from Q1FY24 adding meaningful contribution to the company's revenues. Heranba continues to look forward to create sustainable growth for its stakeholders with its diverse product portfolio, R&D capabilities and prudent growth strategies."



## **Quarterly Performance (Standalone)**


# Net Revenue from Operations

(₹ IN MILLION)




# **EBITDA(incl. Other Rev)** and **EBITDA Margin**

(IN ₹ MILLION & %)




### **PAT and PAT Margin**

(₹ IN MILLION & %)



### **Business Mix**

(IN %)



# **Profit & Loss Summary (Standalone)**

(Quarterly)

Figures in Rs Million, except EPS and Margins

PARTICULARS	Q2FY22	Q1FY23	Q2FY23
Revenue from Operations	3,534	3,619	4,233
Other Income	52	44	40
Total Revenue	3,586	3,664	4,273
Total Expenses	2,972	3,221	3,640
Profit Before Tax	614	443	633
Total Tax Expense	158	106	157
Profit After Tax	456	337	477
EPS Basic (₹)	11.84	8.42	11.92
EPS Diluted (₹)	11.84	8.42	11.92
EBITDA (incl. Other income)	664	507	705
EBITDA (incl. Other income) Margin	18.50%	13.85%	16.49%

# **Profit & Loss Summary (Consolidated)**

(Quarterly)

Figures in Rs Million, except EPS and Margins

PARTICULARS	Q1FY23	Q2FY23
Revenue from Operations	3,619	4,207
Other Income	44	40
Total Revenue	3,664	4,247
Total Expenses	3,221	3,621
Profit Before Tax	440	626
Total Tax Expense	106	106
Profit After Tax	334	472
EPS Basic (₹)	8.36	11.78
EPS Diluted (₹)	8.36	11.78
EBITDA (incl. Other income)	505	698
EBITDA (incl. Other income) Margin	13.78%	16.43%



Section: 04

## **Financial Performance**

**Key Ratios** 

SLIDE 19

**Financial Summary** 


SLIDE 21



## **Key Financial Metrics (Standalone)**


# **Net Revenue from Operations**

(₹ IN MILLION)



# **EBITDA**(incl. Other Rev) and **EBITDA** Margin

(IN ₹ MILLION & %)




# PAT and PAT Margin

(₹ IN MILLION & %)



# Net Debt/(Cash) and Equity




### **Standalone Business Mix**

Diversified customers base across geographies helps to mitigate risks and benefit from expected growth in agrochemical market

### **Revenue from Operations**


(IN%)



### **Revenue from Domestic / Exports**

(% OF SALES)





# **Profit & Loss Summary (Standalone)**

					(Y IIN WILLION)	
PARTICULARS	FY19	FY20	FY21	FY22	H1FY23	
Revenue from Operations	10,044.44	9,513.74	12,186.47	14,503.73	7,852.65	
Other Income	73.94	165.32	70.30	193.50	84.49	
Total Revenue	10,118.38	9,679.06	12,256.77	14,697.23	7,937.14	
Total Expenses	8,897.18	8,390.64	10,173.92	12,144.73	6,861.08	
Profit Before Tax	1,221.2	1,288.42	2,082.85	2,552.50	1,076.06	
Total Tax Expense	467.18	311.85	540.59	661.87	262.17	
Profit After Tax	754.02	976.57	1,542.26	1,890.63	813.89	
EPS Basic (₹)	19.31	25.00	39.41	47.25	20.34	
EPS Diluted (₹)	19.31	25.00	39.41	47.25	20.34	
EBITDA (incl. Other Income)	1,388.07	1,458.82	2,283.69	2,791.07	1,211.87	
EBITDA (incl. Other Income) Margin	13.82%	15.33%	18.74%	19.24%	15.43%	

## **Standalone Balance Sheet** (1/2)

PARTICULARS	FY19	FY20	FY21	FY22	H1FY23
Non-Current Assets					
Property, plant and equipment	511.39	954.41	1,334.35	1,934.26	1940.22
Capital work-in-progress	159.70	377.72	96.95	142.29	350.93
Financial Assets:					
(i) Investments	0.24	37.31	100.98	21.27	6.75
(ii) Loans					5.83
(iii) Other Financial Assets	.71	84.27	241.71	113.62	52.02
Current tax assets (Net)	1.48		10.20	28.06	46.3
Other non-current assets	344.58	80.66	97.01	72.47	195.38
Total Non-Current Assets (I)	1,088.39	1,534.37	1,881.20	2,311.97	2597.42
Current Assets					
Inventories	1,138.94	1,455.18	1,659.86	2,557.39	3435.35
Financial Assets:					
(i) Trade Receivables	2,532.72	2,584.67	3,417.62	4,468.80	5456.71
(ii) Cash and cash equivalents	209.65	31.94	847.80	1198.71	1224.45
(iii) Loans	0	8.95			
(iv) Other financial assets	15.4	17.17	19.97	19.55	20.12
Other current assets	619.33	615.35	606.68	514.73	511.27
Total Current Assets (II)	4,516.04	4,713.26	6,551.93	8,759.19	10,647.90
Total Assets (I + II)	5,604.43	6,247.63	8,433.13	11,071.16	13,245.32

## **Standalone Balance Sheet** (2/2)

					, - ,	
PARTICULARS	FY19	FY20	FY21	FY22	H1FY23	
Equity and liabilities						
Equity						
Equity share capital	390.56	390.56	400.13	400.13	400.13	
Other equity	1891.2	2817.93	4881.21	6,744.45	7481.58	
Total Equity	2281.76	3208.49	5281.34	7,144.58	7,881.71	
Liabilities						
Non-Current Liabilities						
Financial Liabilities						
(i) Borrowings						
(ii) Other Financial Liabilities	57.27	61.46	66.41			
Provisions	4.22	6.49	22.43	78.63	85.91	
Other Non-current liabilities		2.28	11.71	6.34	33.21	
Deferred Tax balances (net)	41.27	16.09				
Total Non-Current Liabilities (I)	102.76	86.32	100.55	84.97	119.20	
Current Liabilities						
Financial Liabilities						
(i) Borrowings	498.74	430.79	502.79	895.64	929.29	
(ii) Trade payables	2352.07	2124.68	1955.82	2,432.38	3693.54	
(iii) Other Financial Liabilities	121.89	139.30	283.27	323.47	447.89	
Current tax Balances (net)	101.68	37.46	88.37	40.06	69.55	
Other current liabilities	96.46	163.19	159.73	126.15	78.83	
Provisions	49.07	57.40	61.25	23.91	25.33	
Total Current Liabilities (II)	3219.91	2952.82	3051.24	3,841.61	5,244.41	
Total Liabilities (I + II)	3322.67	3039.14	3151.79	3,926.58	5,363.61	
TOTAL EQUITY AND LIABILITIES	5604.43	6247.63	8433.13	11,071.16	13,245.32	
				-	-	

## **Standalone Cashflow Statement**

PARTICULARS	FY19	FY20	FY21	FY22	H1FY23
Cash Flow from Operations	877.02	542.11	603.98	981.8	542.81
Cash Flow from Investing Activities	-373.79	-520.39	-407.13	-816.8	-549.46
Cash Flow from financing Activities	-411.35	-199.43	619.01	-62.8	-130.36
Net increase/ (decrease) in cash and cash equivalents	91.88	-177.71	815.86	102.2	-137.0
Cash and cash equivalents at beginning of the year	117.77	209.65	31.94	847.8	950.0
Cash and cash equivalents at end of the year	209.65	31.94	847.80	950.0	813.0



Section: 05

**Strategy for growth** 

**Competetive Strengths** 

SLIDE 26

**Business Strategy** 

SLIDE 27



# **Competitive Strengths**

**Experienced Promoters and Management Team** 



## **Business Strategy**

Well positioned to exploit opportunities offered by growth in Agrochemicals





### Corporate Office

#### **Heranba Industries Ltd.**

2nd Floor, A Wing,

Fortun Avirahi,

Jain Dersar Lane,

Mumbai – 400 092, India

Tel: 91-22-2898 7912/14,

91-22-2898 2133/44, 91-22-2898 4439, 91-22-5070 5050

Email: compliance@heranba.com

#### **Investor Relations Contacts:**

Hiral Keniya

⊠hiral.keniya@in.ey.com

Vikash Verma

☑ vikash.verma1@in.ey.com

